

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
August 2, 2010**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES ACT OF 1933**

**Trius Therapeutics, Inc.**

**File No. 333-162945 - CF#24315**

---

Trius Therapeutics, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on November 6, 2009.

Based on representations by Trius Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.13	through January 31, 2019
Exhibit 10.14	through August 31, 2013
Exhibit 10.15	through March 17, 2014
Exhibit 10.16	through June 15, 2013
Exhibit 10.17	through June 15, 2013

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Jeffrey Riedler  
Assistant Director